{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:22:46Z","timestamp":1770729766227,"version":"3.49.0"},"reference-count":90,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER) funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Portuguese funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Lung cancer has the highest incidence and cancer-related mortality worldwide. In Portugal, it ranks as the fourth most common cancer, with nearly 6000 new cases being diagnosed every year. Lung cancer is the main cause of cancer-related death among males and the third cause of cancer-related death in females. Despite the globally accepted guidelines and recommendations for what would be the ideal path for a lung cancer patient, several challenges occur in real clinical management across the world. The recommendations emphasize the importance of adequate screening of high-risk individuals, a precise tumour biopsy, and an accurate final diagnosis to confirm the neoplastic nature of the nodule. A detailed histological classification of the lung tumour type and a comprehensive molecular characterization are of utmost importance for the selection of an efficacious and patient-directed therapeutic approach. However, in the context of the Portuguese clinical organization and the national healthcare system, there are still several gaps in the ideal pathway for a lung cancer patient, involving aspects ranging from the absence of a national lung cancer screening programme through difficulties in histological diagnosis and molecular characterization to challenges in therapeutic approaches. In this manuscript, we address the most relevant weaknesses, presenting several proposals for potential solutions to improve the management of lung cancer patients, helping to decisively improve their overall survival and quality of life.<\/jats:p>","DOI":"10.3390\/jpm14050446","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:08:32Z","timestamp":1714032512000},"page":"446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5324-8826","authenticated-orcid":false,"given":"Raquel","family":"Ramos","sequence":"first","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"}]},{"given":"Concei\u00e7\u00e3o Souto","family":"Moura","sequence":"additional","affiliation":[{"name":"Pathology Laboratory, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal"}]},{"given":"Mariana","family":"Costa","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"}]},{"given":"Nuno Jorge","family":"Lamas","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"},{"name":"Anatomic Pathology Service, Pathology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio (CHUdSA), Largo Professor Abel Salazar, 4099-001 Porto, Portugal"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, Rua da Universidade, 4710-057 Braga, Portugal"}]},{"given":"Renato","family":"Correia","sequence":"additional","affiliation":[{"name":"Technology & Innovation Department, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal"}]},{"given":"Diogo","family":"Garcez","sequence":"additional","affiliation":[{"name":"Technology & Innovation Department, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal"}]},{"given":"Jos\u00e9 Miguel","family":"Pereira","sequence":"additional","affiliation":[{"name":"Radiology Department, Unilabs Portugal, Rua de Diogo Botelho 485, 4150-255 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-6874","authenticated-orcid":false,"given":"Carlos","family":"Sousa","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J.E.M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer Progress and Priorities: Lung Cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/0141076819843654","article-title":"Lung cancer in never-smokers: A hidden disease","volume":"112","author":"Bhopal","year":"2019","journal-title":"J. R. Soc. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41588-021-00920-0","article-title":"Genomic and evolutionary classification of lung cancer in never smokers","volume":"53","author":"Zhang","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00408-023-00661-3","article-title":"Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening","volume":"201","author":"Daylan","year":"2023","journal-title":"Lung"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","article-title":"Lung cancer in patients who have never smoked\u2014An emerging disease","volume":"21","author":"LoPiccolo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001021","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: Results of a nationwide registry study","volume":"5","author":"Provencio","year":"2020","journal-title":"ESMO Open"},{"key":"ref_9","first-page":"1033","article-title":"Lung cancer screening: History, current perspectives, and future directions","volume":"11","author":"Sharma","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nooreldeen, R., and Bach, H. (2021). Current and Future Development in Lung Cancer Diagnosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168661"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3322\/caac.21811","article-title":"Screening for lung cancer: 2023 guideline update from the American Cancer Society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.biopha.2018.07.145","article-title":"Current trends and emerging diagnostic techniques for lung cancer","volume":"106","author":"Prabhakar","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial","volume":"382","author":"Scholten","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jama.2021.0377","article-title":"Screening for Lung Cancer with Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"325","author":"Jonas","year":"2021","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ypmed.2016.04.015","article-title":"Screening for lung cancer: A systematic review and meta-analysis","volume":"89","author":"Miller","year":"2016","journal-title":"Prev. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of Non-Small Cell Lung Cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shen, Y.-C., Chen, C.-H., and Tu, C.-Y. (2021). Advances in Diagnostic Bronchoscopy. Diagnostics, 11.","DOI":"10.3390\/diagnostics11111984"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.21037\/jtd.2016.02.12","article-title":"The optimal sequence for bronchial brushing and forceps biopsy in lung cancer diagnosis: A random control study","volume":"8","author":"Hou","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2017.09.002","article-title":"Flexible Bronchoscopy","volume":"39","author":"Miller","year":"2018","journal-title":"Clin. Chest Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pulmoe.2020.06.007","article-title":"Bronchoscopic sampling techniques in the era of technological bronchoscopy","volume":"28","author":"Mondoni","year":"2022","journal-title":"Pulmonology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.25259\/IJMIO_31_2022","article-title":"Role of fiberoptic bronchoscopy-guided needle aspiration cytology (EBNA) in diagnosing lung cancer in endobronchial lesions: A single-center experience","volume":"8","author":"Patil","year":"2023","journal-title":"Int. J. Mol. Immuno Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thoraxjnl-2015-206985","article-title":"EBUS-guided mediastinal lung cancer staging: Monitoring of quality standards improves performance","volume":"71","author":"Matthew","year":"2016","journal-title":"Thorax"},{"key":"ref_25","first-page":"545","article-title":"To evaluate the role of sputum in the diagnosis of lung cancer in south Indian population","volume":"2","author":"Muniyappa","year":"2017","journal-title":"Int. J. Res. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3747\/co.22.2563","article-title":"Pleural Fluid Tumour Markers in Malignant Pleural Effusion with Inconclusive Cytologic Results","volume":"22","author":"Antonangelo","year":"2015","journal-title":"Curr. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/resp.12467","article-title":"Differentiating benign from malignant mediastinal lymph nodes visible at EBUS using grey-scale textural analysis","volume":"20","author":"Edey","year":"2015","journal-title":"Respirology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications","volume":"16","author":"Marino","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1634\/theoncologist.2015-0523","article-title":"The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer","volume":"21","author":"Horn","year":"2016","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_32","first-page":"201","article-title":"Molecular profiling in lung cancer","volume":"15","author":"Nagl","year":"2022","journal-title":"Memo Mag. Eur. Med. Oncol."},{"key":"ref_33","first-page":"503","article-title":"Lung cancer biomarkers, targeted therapies and clinical assays","volume":"4","author":"Patel","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4132\/jptm.2017.04.10","article-title":"Molecular Testing of Lung Cancers","volume":"51","author":"Shim","year":"2017","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.21037\/tlcr.2017.08.03","article-title":"Molecular diagnostics of lung cancer in the clinic","volume":"6","author":"Sholl","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non\u2013Small Cell Lung Cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, D., Savic Prince, S., and Rothschild, S.I. (2021). Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 13.","DOI":"10.3390\/cancers13040804"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.esmoop.2023.101587","article-title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: Expert consensus on the rationale and considerations for implementation","volume":"8","author":"Gosney","year":"2023","journal-title":"ESMO Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: Current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2006.04.022","article-title":"The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies","volume":"9","author":"Ji","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12094-019-02218-4","article-title":"Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology","volume":"22","author":"Garrido","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sforza, V., Palumbo, G., Cascetta, P., Carillio, G., Manzo, A., Montanino, A., Sandomenico, C., Costanzo, R., Esposito, G., and Laudato, F. (2022). BRAF Inhibitors in Non-Small Cell Lung Cancer. Cancers, 14.","DOI":"10.3390\/cancers14194863"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3322\/caac.21774","article-title":"Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide","volume":"73","author":"Fox","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"107522","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107438","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12272-019-01126-z","article-title":"Targeting epigenetics for cancer therapy","volume":"42","author":"Park","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15592294.2016.1237345","article-title":"Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives","volume":"11","author":"Schiffmann","year":"2016","journal-title":"Epigenetics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pujol, N., Heeke, S., Bontoux, C., Boutros, J., Ili\u00e9, M., Hofman, V., Marquette, C.-H., Hofman, P., and Benzaquen, J. (2022). Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101684"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2017_16","article-title":"Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer","volume":"249","author":"Facchinetti","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737140.2020.1787156","article-title":"Molecular therapeutic targets in non-small cell lung cancer","volume":"20","author":"Sankar","year":"2020","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","article-title":"Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1078-0432.CCR-18-3829","article-title":"On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation","volume":"25","author":"Brown","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/17476348.2020.1721285","article-title":"Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer","volume":"14","author":"Pinto","year":"2020","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcb.27437","article-title":"Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase","volume":"120","author":"Goyal","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: Implications for therapeutic strategies","volume":"27","author":"Shaw","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00063","article-title":"Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer","volume":"2017","author":"Gainor","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12094-022-02849-0","article-title":"BRAF\/MEK inhibition in NSCLC: Mechanisms of resistance and how to overcome it","volume":"25","author":"Tsamis","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"769124","DOI":"10.3389\/fonc.2022.769124","article-title":"Research Progress of Anti-PD-1\/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC","volume":"12","author":"Bie","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: Lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"Teng","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Casagrande, G.M.S., Silva, M.D.O., Reis, R.M., and Leal, L.F. (2023). Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032505"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gale, D., Lawson, A.R.J., Howarth, K., Madi, M., Durham, B., Smalley, S., Calaway, J., Blais, S., Jones, G., and Clark, J. (2018). Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194630"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hofman, P. (2021). Next-Generation Sequencing with Liquid Biopsies from Treatment-Na\u00efve Non-Small Cell Lung Carcinoma Patients. Cancers, 13.","DOI":"10.3390\/cancers13092049"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hofman, V., Heeke, S., Marquette, C.-H., Ili\u00e9, M., and Hofman, P. (2019). Circulating Tumor Cell Detection in Lung Cancer: But to What End?. Cancers, 11.","DOI":"10.3390\/cancers11020262"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e038937","DOI":"10.1136\/bmjopen-2020-038937","article-title":"Regional differences in tobacco smoking and lung cancer in Portugal in 2018: A population-based analysis using nationwide incidence and mortality data","volume":"10","author":"Forjaz","year":"2020","journal-title":"BMJ Open"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pulmoe.2021.09.001","article-title":"Lung cancer survival and sex-specific patterns in Portugal: A population-based analysis","volume":"29","author":"Guerreiro","year":"2023","journal-title":"Pulmonology"},{"key":"ref_80","first-page":"e52194","article-title":"Beta-Adrenergic Blockade in Advanced Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Multicentric Study","volume":"16","author":"Freitas","year":"2024","journal-title":"Cureus"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Pereira-Nunes, A., Ferreira, H., Abreu, S., Guedes, M., Neves, N.M., Baltazar, F., and Granja, S. (2023). Combination Therapy with CD147-Targeted Nanoparticles Carrying Phenformin Decreases Lung Cancer Growth. Adv. Biol., 7.","DOI":"10.1002\/adbi.202300080"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"10","DOI":"10.20344\/amp.19487","article-title":"Implementation of a Pilot Study to Analyze Circulating Tumor DNA in Early-Stage Lung Cancer","volume":"37","author":"Machado","year":"2023","journal-title":"Acta M\u00e9dica Port."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"559","DOI":"10.20344\/amp.16847","article-title":"Lung Cancer Screening: Low-Dose Thoracic Computed Tomography Performed in a High-Risk Portuguese Population","volume":"36","author":"Abreu","year":"2023","journal-title":"Acta M\u00e9dica Port."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker Testing for Patients with Advanced Non\u2013Small Cell Lung Cancer: Real-World Issues and Tough Choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Simoff, M.J., Ost, D., Wagner, O.J., Lavin, J., Nauman, B., Hsieh, M.-C., Wu, X.-C., Pettiford, B., and Shi, L. (2021). Understanding the patient journey to diagnosis of lung cancer. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08067-1"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcancer.2023.01.006","article-title":"Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective","volume":"89","author":"Huang","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e187430642207060","DOI":"10.2174\/18743064-v16-e2207060","article-title":"The Journey for Lung Cancer Screening where we Stand Today","volume":"16","author":"Wahla","year":"2022","journal-title":"Open Respir. Med. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/resp.13963","article-title":"Lung cancer screening implementation: Complexities and priorities","volume":"25","author":"Rankin","year":"2020","journal-title":"Respirology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cllc.2019.07.009","article-title":"Clinical Features and Progression Pattern of Acquired T790M-positive Compared with T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity over Time through Liquid Biopsy","volume":"21","author":"Lorenzi","year":"2020","journal-title":"Clin. Lung Cancer"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/5\/446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:36Z","timestamp":1760106816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/5\/446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":90,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jpm14050446"],"URL":"https:\/\/doi.org\/10.3390\/jpm14050446","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]}}}